Evolution of Nerve Conduction Demyelinating Parameters Between Baseline and Treatment Cessation May Not Be Predictive of Relapse in IVIg ‐Responsive CIDP Patients
Muscle & Nerve · 2026-06 · 73 (6) · 984-989
DOI: 10.1002/mus.70199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 06.03.2026. Verfasst von Marine Le Vavasseur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Physiologie Clinique-Explorations Fonctionnelles, APHP, DMU DREAM, Hôpital Lariboisière, Paris, France. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Intravenous, Neural Conduction, Immunologic Factors. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction/Aims Identifying factors associated with short‐term relapse is essential for tailoring maintenance treatment on a case‐by‐case basis in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We sought to determine whether changes in demyelinating electrophysiological features during treatment could predict relapse after treatment discontinuation in a cohort of CIDP patients.
Methods
We conducted a retrospective study of patients with CIDP treated with intravenous immunoglobulin (IVIg), all of whom had a first nerve conduction study (NCS) at treatment initiation or during treatment, while the disease was in a stable phase, followed by a second study at the time of treatment discontinuation. Demyelinating features and the degree of axonal loss were determined during each NCS and compared between the two examinations.
Results
Thirty‐one consecutive IVIg‐responsive CIDP patients were included, with a mean age of 59.1 ± 14.6 years. Twenty (65%) were males. Sixteen patients (52%) relapsed after a mean of 6 months. Most patients demonstrated a reduced total number and type of demyelinating features between the two assessments, but overall, these changes were not different between the relapse and relapse‐free groups. Similarly, axonal loss at our first assessment and the progression of axonal loss between our two assessments were not different in the relapse group compared to the relapse‐free group.
Discussion
In our population of IVIg responsive CIDP patients, we were unable to demonstrate the predictive value of follow‐up nerve conduction studies alone for the risk of relapse. Looking at other biomarkers alone or in combination with NCS is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Physiologie Clinique-Explorations Fonctionnelles, APHP, DMU DREAM, Hôpital Lariboisière, Paris, France.
- Service de Neurologie, Groupe Hospitalier Paris Saint Joseph, Paris, France.
- Université Paris Cité, INSERM UMRS-1144, Paris, France.
- Centre de compétence Neuropathies Rares et amyloïdes Ile-de France Caraïbes (CERAMIC), FILNEMUS, AP-HP, Hôpital Lariboisière, Paris, France.
Zitieren
APA
Le Vavasseur, M., Blaise, C., Cordelle, I., Reach, P., Chakroun, S., Kubis, N., & Lozeron, P. (2026). Evolution of Nerve Conduction Demyelinating Parameters Between Baseline and Treatment Cessation May Not Be Predictive of Relapse in IVIg ‐Responsive CIDP Patients. Muscle & Nerve, 73(6), 984-989. https://doi.org/10.1002/mus.70199
Vancouver
Le Vavasseur M, Blaise C, Cordelle I, Reach P, Chakroun S, Kubis N, et al. Evolution of Nerve Conduction Demyelinating Parameters Between Baseline and Treatment Cessation May Not Be Predictive of Relapse in IVIg ‐Responsive CIDP Patients. Muscle & Nerve. 2026;73(6):984-989. doi:10.1002/mus.70199
BibTeX
@article{LeVavasseur2026,
author = {Le Vavasseur, Marine and Blaise, Capucine and Cordelle, Isabelle and Reach, Pauline and Chakroun, Sahar and Kubis, Nathalie and Lozeron, Pierre},
title = {Evolution of Nerve Conduction Demyelinating Parameters Between Baseline and Treatment Cessation May Not Be Predictive of Relapse in IVIg ‐Responsive CIDP Patients},
journal = {Muscle & Nerve},
year = {2026},
volume = {73},
number = {6},
pages = {984--989},
doi = {10.1002/mus.70199}
}
EUVIMED